Assessment of the Concentration of Endogenous Factors Regulating Angiogenesis, VASH-1 and VEGF-A, in the Blood Serum of Patients with Neuroendocrine Neoplasms.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
11
2021
revised:
03
02
2022
accepted:
05
02
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Neuroendocrine neoplasms (NENs) constitute about 2% of all malignant neoplasms, and the angiogenesis process in these tumors is still of a great interest. Vasohibin-1 (VASH-1) is an angiogenesis inhibitor, while vascular endothelial growth factor A (VEGF-A) is one of the main factors promoting vascular formation. The subject of this study was to assess serum concentration of these factors in patients with diagnosed NEN and in control group.
Identifiants
pubmed: 35372578
doi: 10.1155/2022/9084393
pmc: PMC8966743
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Biomarkers
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9084393Informations de copyright
Copyright © 2022 Janusz Strzelczyk et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this article.
Références
Ann Clin Lab Sci. 2000 Apr;30(2):175-8
pubmed: 10807161
Med Oncol. 2012 Dec;29(4):2718-26
pubmed: 22438034
Oncol Lett. 2018 Oct;16(4):5265-5274
pubmed: 30250596
J Endocrinol. 2000 Jun;165(3):703-14
pubmed: 10828855
Endokrynol Pol. 2011;62(5):456-64
pubmed: 22069107
Mol Cancer. 2019 Dec 10;18(1):181
pubmed: 31823788
Pathol Oncol Res. 2020 Jul;26(3):1787-1795
pubmed: 31676993
J Clin Oncol. 2008 Jul 10;26(20):3403-10
pubmed: 18612155
Am J Pathol. 2009 Jul;175(1):430-9
pubmed: 19498005
Endocr Pathol. 2008 Winter;19(4):282-8
pubmed: 18931958
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Endokrynol Pol. 2012;63(5):362-6
pubmed: 23115069
Ann Clin Biochem. 1994 May;31 ( Pt 3):215-32
pubmed: 7520678
J Interferon Cytokine Res. 2013 Aug;33(8):428-33
pubmed: 23651239
Hepatogastroenterology. 2005 May-Jun;52(63):731-41
pubmed: 15966194
Cancer. 2008 Jul 1;113(1):5-21
pubmed: 18473355
Diagnostics (Basel). 2020 Oct 29;10(11):
pubmed: 33138020
J Clin Oncol. 1995 Mar;13(3):681-7
pubmed: 7533826
Am J Transl Res. 2020 Jan 15;12(1):118-129
pubmed: 32051741
PLoS One. 2018 May 22;13(5):e0197035
pubmed: 29787601
Hum Pathol. 2014 Apr;45(4):866-74
pubmed: 24656098
Health Sci Rep. 2018 May 17;1(6):e40
pubmed: 30623077
Science. 1987 Jan 23;235(4787):442-7
pubmed: 2432664
Cancer Biol Ther. 2017 Nov 2;18(11):827-832
pubmed: 28886304
Cancer Sci. 2019 Jul;110(7):2296-2308
pubmed: 31074083
Hepatology. 2014 Aug;60(2):633-47
pubmed: 24390792
Tohoku J Exp Med. 2017;243(2):107-114
pubmed: 29057763
Turk J Med Sci. 2018 Jun 14;48(3):576-583
pubmed: 29914255
J Clin Med. 2020 May 06;9(5):
pubmed: 32384679
PLoS One. 2014 Jun 10;9(6):e96932
pubmed: 24915146
Med Oncol. 2014 Feb;31(2):816
pubmed: 24366689
Cancer Sci. 2021 Jan;112(1):243-253
pubmed: 33128283
Vascul Pharmacol. 2012 May-Jun;56(5-6):262-6
pubmed: 22286022
J Diabetes Complications. 2019 Jul;33(7):477-484
pubmed: 31097304
Zhonghua Wei Chang Wai Ke Za Zhi. 2015 Mar;18(3):272-6
pubmed: 25809333
Oncology. 2005;69 Suppl 3:4-10
pubmed: 16301830
Exp Ther Med. 2017 Oct;14(4):3477-3484
pubmed: 29042936
Tumour Biol. 2014 Nov;35(11):10615-25
pubmed: 25230786
Oncotarget. 2017 Dec 07;9(12):10203-10210
pubmed: 29535800
Endokrynol Pol. 2017;68(2):79-110
pubmed: 28597909
Hum Pathol. 2014 Mar;45(3):589-97
pubmed: 24444468
Diabetologia. 2009 Feb;52(2):359-61
pubmed: 19057892
Anticancer Res. 2014 Oct;34(10):5321-9
pubmed: 25275025
Br J Cancer. 2013 May 28;108(10):2123-9
pubmed: 23591203
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Mol Cell Endocrinol. 2016 Apr 15;425:61-8
pubmed: 26805636